Astrazeneca (AZN) Income from Non-Controlling Interests (2009 - 2026)

Astrazeneca's Income from Non-Controlling Interests history runs 18 years deep, the most recent figure standing at $1.0 million for Q2 2026.

• In Q2 2026, Income from Non-Controlling Interests rose 150.0% year-over-year to $1.0 million; the TTM figure through Jun 2026 stood at $13.0 million (up 62.5% YoY), while the FY2025 annual figure was $16.0 million, up 166.67% from the prior year.
• Income from Non-Controlling Interests for Q2 2026 stood at $1.0 million, roughly flat from $1.0 million in the prior quarter.
• The five-year high for Income from Non-Controlling Interests was $9.0 million in Q4 2025, with the low at -$2.0 million in Q2 2025.
• The 5-year median for Income from Non-Controlling Interests is $1.0 million (2022), against an average of $2.0 million.
• Peak annual rise in Income from Non-Controlling Interests reached 1000.0% in 2025, while the deepest fall reached 300.0% in 2025.
• Astrazeneca's Income from Non-Controlling Interests stood at $1.0 million in 2022, then slumped by 200.0% to -$1.0 million in 2023, then changed by 0.0% to -$1.0 million in 2024, then jumped by 1000.0% to $9.0 million in 2025, then plunged by 88.89% to $1.0 million in 2026.
• Business Quant data shows AZN's Income from Non-Controlling Interests at $1.0 million in Q2 2026, $1.0 million in Q1 2026, and $9.0 million in Q4 2025.